Aktiesnakken — Juni 2016
-
Via twitter dukker fantatiske Novo nyheder op
-
5% op i morgen på Novo
-
New Orleans, US, 13 June 2016 – Novo Nordisk today announced that Victoza
(liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to standard of care in 9,340 adults with type 2 diabetes at high CV risk. The main results of the LEADER trial were presented today at the American Diabetes Association -
There was a significant 22% reduction in cardiovascular death with Victoza
treatment vs placebo (95% CI: 0.66; 0.93, p=0.007) and reductions in non-fatal myocardial infarction (HR=0.88, 95% CI: 0.75; 1.03, p=0.11) and non-fatal stroke (HR=0.89, 95% CI: 0.72; 1.11, p=0.30).1, 2 -
Er det godt eller skide godt ??
-
Åbenbart så er disse Victoza Data nok som forventet.
-
God morgen.
-
En god gennem omkring data på Victosa. http://www.proinvestor.com/investornyt/377774/novo-victoza-vaekker-laeger-og-diabetikere-til-live
-
gennemgang
-
I forhold til forventningerne fra Citigroup er data lidt skuffende: https://www.landbobanken.dk/investering/aktiefokus
-
Godmorgen fellas
-
Fra Danske Bank: "NOVO NORDISK: robust data from Leader trail, 13% reduction for GPP-1 even if
we hoped for a bit more good enough, +tive effect on all CV
endpoints. We reiterate BUY & TP 470."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind